MultiplAI leverages genomics and AI to provide universal remote screening for cardiovascular diseases among other complex diseases. We use a liquid biopsy of whole blood based on RNA sequencing and deep learning looking at all biomarkers in the blood, thus creating a superb biomarker to detect diseases earlier. Our test can be used in continuous testing both for preventative screening and post-treatment monitoring. Given that it requires only a simple blood sample, it can be administered remotely, anywhere, and costs a fraction of existing diagnostic methods.
MultiplAI brings together maturing artificial intelligence algorithms, cost-effective sequencing, and remote medicine to detect cardiovascular and other complex diseases and better establish prognosis based on the biological substrate.
Total Funding: N/A
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2019
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at MultiplAI Health